ÂÜÀòÂÒÂ×

Dr. Meyers has over 25 years of drug discovery experience at several highly successful startup companies. He was most recently the Director of Chemistry at Suntory Pharmaceutical Research Laboratories (SPRL), where he led a team of chemists in the protein structure guided design of serine protease and kinase inhibitors. Prior to that, he was a Chemistry Director at New Chemical Entities (NCE), a natural products drug discovery company subsequently acquired by Albany Molecular.

As Head at Sphinx Pharmaceuticals, he lead the development of combinatorial chemistries and enabling technologies that contributed to the acquisition of Sphinx by Eli Lilly. Prior to joining Sphinx, he was one of the first scientists at Vertex Pharmaceuticals, where he worked on the rational design of small molecule inhibitors. Dr. Meyers received a Ph.D. in Organic Chemistry from Yale University, and completed his postdoctoral studies at Columbia University.